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Abstract We have developed a new type of long-circulating 
immunoliposome (Fab'-PEG immunoliposomes) which is effi-
ciently extravasated into the targeted solid tumor in vivo. Small 
unilamellar liposomes (100-130 nm in diameter) were prepared 
from distearoylphosphatidylcholine (DSPC), cholesterol 
(CHOL) and a dipalmitoylphosphatidylethanolamine derivative 
of PEG with a terminal maleimidyl group (DPPE-PEG-Mal), 
and conjugated Fab' fragment of antibody. Inclusion of DPPE-
PEG-Mal and linkage of the Fab' fragment instead of intact 
antibody to PEG terminals allowed the liposomes to evade RES 
uptake and remain in the circulation for a long time, resulting in 
enhanced accumulation of the liposomes in the solid tumor. 
Because of the ability of such Fab'-PEG immunoliposomes to 
target solid tumors, they appear highly attractive as carriers of 
not only chemotherapeutic agents, but also of macromolecular 
drugs. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Drug delivery to a specific site by immunoliposomes repre-
sents a potentially attractive mode of therapy. However, 
although immunoliposomes bind effectively and specifically 
to target cells in vitro, their targeting efficiency in vivo is 
relatively low. Studies in vivo have revealed that coating lip-
osomes with antibody leads to enhanced uptake of the immu-
noliposomes by the reticuloendothelial system (RES) [1,2] and 
the immunotargeting efficiency depends on the antibody den-
sity on the surface [3]. Thus, highly efficient targeting and a 
relatively low level of RES uptake of the immunoliposomes 
are apparently mutually exclusive. Recently, RES-evading, 
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long-circulating liposomes have been prepared by coating the 
liposome surface with amphipathic polyethyleneglycols (PEG) 
[4-7]. 
We have reported a new type of PEG immunoliposome 
which can effectively bind to target cells in vivo [8]. This 
was achieved by the use of newly synthesized distearoyl-iV-
(3-carboxypropionoyl)polyethyleneglycol phosphatidyletha-
nolamine (DSPE-PEG-COOH) to couple antibodies directly 
to the distal terminal of PEG chains. The conjugation of a 
monoclonal IgG antibody, 34A, which is highly specific to 
pulmonary endothelial cells, to the PEG terminal enabled ex-
cellent target binding and retention of the immunoliposomes. 
However, it should be noted that the target sites for 34A-
PEG immunoliposomes are readily accessible, i.e. on the vas-
cular endothelial surface. For a much less accessible target, 
such as tumor cell surface antigens in a solid tumor, the tar-
geting efficiency of immunoliposomes is likely to be low. 
Nevertheless, the capillary permeability of the endothelial 
barrier in newly vascularized tumors is significantly greater 
than that of normal organs [9]; we and others have demon-
strated that long-circulating liposomes of small size (=sl00 
nm mean diameter) and rigid lipid composition are signifi-
cantly accumulated in solid tumors [10-12]. Further, the em-
ployment of antibody Fab' fragments instead of whole IgG, 
would reduce RES uptake via the Fc receptor-mediated mech-
anism. Since the thiol residues of Fab' fragments permit con-
jugation with retention of the antigen-binding activity of the 
intact antibody, it has been proposed that small PEG immu-
noliposomes bearing antibody Fab' fragments at the PEG 
terminals might exhibit prolonged circulation and pass fairly 
readily through the leaky tumor endothelium by passive con-
vective transport. 
In order to test this hypothesis, we have synthesized a di-
palmitoyl phosphatidylethanolamine derivative of PEG with a 
terminal maleimidyl group for the preparation of Fab'-PEG 
immunoliposomes (Fig. 1). The monoclonal antibody 21B2 
(IgGl), specific for the human carcinoembryonic antigen 
(CEA), was used in this study [13]. The targeting ability of 
Fab'-PEG immunoliposomes was examined by using CEA-
positive human gastric cancer strain MKN-45 cells inoculated 
into BALB/c nulnu mice. 
2. Materials and methods 
2.1. Materials 
DSPC and DPPE were kindly donated by Nippon Oil and Fats 
(Tokyo, Japan). CHOL was purchased from Wako Pure Chemicals 
(Osaka, Japan). DPPE-PEG-COOH was synthesized as described [8]. 
The average molecular weight of PEG was 3000. 
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2.2. Preparation of DPPE-PEG-Mal 
The dipalmitoylphosphatidylethanolamine derivative of PEG with a 
terminal maleimidyl group (DPPE-PEG-Mal, Fig. 1) was synthesized 
according to [14] with minor modifications. Briefly, an aliquot of 
polyoxyethylene bis(amine) with an average molecular weight of 
3350 was dissolved in chloroform, and JV-(e-maleimidocaproyloxy)-
succinimide (Dojin Lab. Kumamoto) was added thereto. The reaction 
was allowed to continue until the ninhydrin reaction became negative. 
The resulting dimaleimide PEG was purified on a silica gel column 
with a chloroform-methanol gradient. Two molar equivalents of di-
maleimide PEG was reacted with a thiol-modified DPPE, which was 
synthesized by adding 20 mg of iminothiolane (Sigma) and 25 |xl of 
triethylamine to DPPE (84 mg) dissolved in a mixture of chloroform-
methanol (1:1, v/v), under nitrogen gas (conversion of the amino 
group to a thiol group was confirmed by the negative ninhydrin re-
activity and the acquired reactivity with fluorescein maleimide (Funa-
koshi, Tokyo)). The reaction mixture was evaporated, dissolved in 
chloroform and passed through a silica gel column as above. The 
fraction containing DPPE-PEG-Mal was dried in vacuo and dispersed 
in a small amount of water to form micelles. The DPPE-PEG-Mal 
solution was ultrafiltered with an Amicon membrane (XM-50) to re-
move non-micelle-forming impurities and the product was lyophilized. 
The yield of DPPE-PEG-Mal was approximately 20%. The formation 
of DPPE-PEG-Mal was confirmed by NMR. 
2.3. Preparation of anti-human CEA monoclonal antibodies and 
their Fab' fragments 
The monoclonal antibody 21B2 (IgGl), specific for the human car-
cinoembryonic antigen (CEA), was prepared as described [13]. 21B2 
was isolated from BALB/c mice after immunization with human CEA 
antigen purified from a CEA-producing human gastric cancer strain 
MKN-45 cells. Fab' fragments of 21B2 were prepared by pepsin di-
gestion of the antibody and 2-aminoethanethiol reduction of the 
F(ab')2 fragments, as described previously [15]. Antibodies and frag-
ments were radiolabeled with 125I, using the IODO-GEN method, to a 
specific activity of 2-5 X105 cpm/ug. The antigen-binding activity of 
the Fab' fragment was confirmed by cell binding assay with MKN-45 
cells in vitro. 
2.4. Preparation of immunoliposomes 
PEG-liposomes were composed of DSPC/CHOL/DPPE-PEG-Mal 
(2:1:0.2, molar ratio) with [3H]cholesteryl hexadecylether (NEN, Bos-
ton, MA) as an inert membrane marker [2]. Small unilamellar lip-
osomes (SUV) were prepared by reverse-phase evaporation [16] fol-
lowed by extrusion (Lipex Biomembranes, Canada) through two 
stacked polycarbonate membrane filters (Nuclepore Co., CA) of 
0.1 |xm diameter. PBS (pH 6.5) was used as the liposomal aqueous 
phase. The extruded liposomes were centrifuged at 200 000 Xg for 
15 min at 4°C (Hitachi CS120, S100AT5 rotor), and then resuspended 
in PBS (pH 6.5). To 1 ml of PEG-liposomes (2 mg lipids 
(DSPC+CHOL)), the Fab' fragments (0.3-1 mg) with a trace amount 
of 125I-labelled Fab' were added, and the mixture was incubated for 
2 h at room temperature. The immunoliposomes were separated from 
unbound protein on a BioGel A 15m column preequilibrated with 
saline. As control immunoliposomes, IgG-PEG immunoliposomes 
were prepared by conjugation of the intact antibody to liposomes 
composed of DSPC, Choi, and DPPE-PEG-COOH (2:1:0.2, molar 
ratio) as described previously [8]. Liposome size was measured by a 
Nicomp 370 HPL submicron particle analyzer (HIAC Pacific Scien-
tific, CA). All liposomes were prepared to be of similar, homogeneous, 
small size (100-130 nm in diameter). The lipid concentration and the 
coupling efficiency of Fab' fragment were estimated by phosphorus 
assay [17] and from the radioactivity of 125I, respectively. The average 
number of antibody molecules per liposome was calculated as de-
scribed previously [8]. The coupling efficiency of the whole antibody 
of 21B2 to PEG-COOH liposomes was approximately 20-30%. In 
contrast, that of Fab' fragment to PEG-Mal liposomes was approx-
imately 60-70%. 
2.5. In vitro and in vivo studies 
The human CEA-positive gastric cancer cell line, MKN-45, was 
maintained in culture flasks in complete E-RDF medium (Kyokuto 
Co., Tokyo) supplemented with 10% FCS (Filtron Pty Ltd., Austral-
ia). In vitro cell binding was studied using [3H]cholesteryl hexadecyl-
ether-labeled PEG immunoliposomes. MKN-45 cells, grown as mono-
layers in 35 mm culture dishes, were incubated with liposomes at 
varying lipid concentrations for 90 min at 4°C. After the incubation, 
cells were washed, trypsinized, and solubilized with Soluene 350 
(Packard Instruments, IL) then the radioactivity was counted in 
Hionic-Fluor scintillation mixture in an Aloka LSC-3000 counter 
(Aloka Co., Tokyo). 
The tissue distribution of PEG immunoliposomes was examined by 
using MKN-45-bearing BALB/c nulnu mice. Two million cells in 
100 (il were inoculated into the back of female BALB/c nulnu mice 
(Nihon Clea Co., Tokyo). When the estimated tumor weight (cal-
culated as 1/2 X length X width2) [18] reached about 300 mg, the 
mice were used for experiments. [3H]cholesteryl hexadecylether-
labeled PEG immunoliposomes were injected into MKN-45-bearing 
BALB/c nulnu mice (3-5/group) via the tail vein. At selected time 
intervals after administration, mice were lightly anesthetized, bled 
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Fig. 1. Structure of DPPE-PEG-Mal and schematic illustration of Fab'-PEG immunoliposome. 
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Fig. 2. In vitro cell binding of PEG immunoliposomes. Binding of 
PEG-Mal liposomes (■), IgG-PEG immunoliposomes ([70], A) or 
Fab'-PEG immunoliposomes ([517], •) was plotted as a function of 
added lipid. Liposomes were incubated at varying lipid concentra-
tions with MKN-45 cells for 90 min at 4°C. The number in square 
brackets represents the average number of antibody or Fab' mole-
cules per liposome. 
by eye puncture, killed by cervical dislocation and dissected. The radio-
activity of each internal organ was determined as described above. 
The stability of IgG-PEG-COOH conjugation or Fab'-PEG-Mal 
conjugation in immunoliposomes was checked in 90% mouse serum at 
37°C. 125I-labeled antibodies and [3H]cholesteryl hexadecylether-la-
beled immunoliposomes were used. Liposomal samples from the in-
cubation mixture were separated by the a BioGel A 15m column and 
the cleavage of conjugation was determined from the ratio of radio-
activity. 
3. Results and discussion 
As specific association of immunoliposomes with their tar-
get cells is a necessary requirement for target-specific drug 
delivery, we first tested whether these PEG immunoliposomes 
specifically bound to the target cells in vitro. As shown in Fig. 
2, PEG immunoliposomes conjugated with either whole anti-
body (IgG) or Fab' fragment readily bound with MKN-45 
cells. The degree of target cell binding of immunoliposomes 
was superior to that of nontargeted PEG-Mal liposomes. The 
differences in cell binding between IgG-PEG and Fab'-PEG 
immunoliposomes were due to the variation of coupled num-
ber of antibody or Fab' fragment. These results revealed that 
free PEG (not linked to antibody) in liposomes does not in-
terfere sterically with antigen-binding of the antibody or Fab' 
fragment. 
The cleavage of IgG-PEG-COOH conjugation or Fab ' -
PEG-Mal conjugation in mouse serum was not observed 
over 12 h in incubation with mouse serum at 37°C (data 
not shown). Both conjugation may be stable in vivo and anti-
bodies and fragments remain with the liposome after i.v. in-
jection. We investigated whether the use of Fab' fragment 
instead of whole antibody (IgG) would modify the pattern 
of tissue distribution of immunoliposomes. As shown in Fig. 
3, PEG-Mal liposomes without antibody showed prolonged 
residence in the circulation and low liver uptake, regardless 
of the presence of the terminal maleimidyl group. There were 
no marked differences in tissue distribution among liposomes 
containing DPPE-PEG, DPPE-PEG-COOH and DPPE-PEG-
Mal, taking into account our previous results [4,7,8]. DPPE-
PEG has an -OCH3 residue at the terminal and is used for the 
preparation of conventional PEG-liposomes. IgG-PEG im-
munoliposomes, bearing approximately 51 whole antibody 
molecules per liposome, were rapidly cleared from the blood 
and were found entirely in the liver. In contrast, Fab'-PEG 
immunoliposomes, bearing approximately 517 Fab' molecules 
per liposome, were retained longer in the circulation with a 
concomitant decrease in the liver uptake compared with IgG-
PEG immunoliposomes. These results indicate that the link-
age of whole IgG to the PEG terminal enhances RES uptake 
via the Fc receptor-mediated mechanism [1,2]. In the case of 
Fab'-PEG immunoliposomes, the absence of the Fc portion 
and the presence of free PEG-Mal (not linked to Fab' frag-
ment) may both play a role in the prolonged circulation of the 
liposomes. As we pointed out previously [8], Fab' fragment is 
much better than whole IgG in terms of designing PEG im-
munoliposomes with a prolonged circulation time. Further, 
the usage of Fab' fragment should greatly reduce the antigen-
icity. 
Fig. 4 shows the accumulation of liposomes, with an aver-
age diameter of 100-130 nm, the solid tumor at 24 h after 
injection. Relatively high accumulation into the tumor tissue 
was obtained with PEG-COOH liposomes, PEG-Mal lipo-
somes and Fab'-PEG immunoliposomes. These results were 
clearly correlated to the prolonged circulation time (Fig. 3). 
The accumulation of Fab'-PEG immunoliposomes was 2-fold 
100" 
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Fig. 3. Time course of blood residence and liver uptake of PEG-Mal liposomes (o), IgG-PEG immunoliposomes ([51], A) or Fab'-PEG im-
munoliposomes ([517], • ) . 
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Fig. 4. Accumulation of immunoliposomes in solid tumor in MKN-
45-bearing BALB/c nulnu mice at 24 h after injection. The number 
in square brackets represents the average number of antibody or 
Fab' molecules per liposome. 
higher than that of IgG-PEG immunoliposomes or bare lip-
osomes, and equal to that of PEG-Mal or PEG-COOH lip-
osomes. The permeability of tumor vasculature is generally 
increased as compared to normal tissue [9,19], so Fab'-PEG 
immunoliposomes could extravasate through the leaky endo-
thelium by passive convective transport. It is known, however, 
that the size limitation of such liposomes is of practical sig-
nificance. Under physiological tumor condition, only lipo-
somes with small size and prolonged circulation time have a 
sufficient chance to encounter the leaky vessel of the tumor. 
The higher concentration and longer blood residence time of 
Fab'-PEG immunoliposomes may have improved the effi-
ciency of extravasation. IgG-PEG immunoliposomes showed 
a short circulation time due to a high liver uptake as shown in 
Fig. 3, so that they have not sufficient concentration and 
residence time for extravasation through the leaky endothe-
lium. Though there were no differences in accumulation into 
solid tumor between Fab'-PEG immunoliposomes and PEG 
liposomes without antibodies, only Fab'-PEG immunolipo-
somes stand a better chance of binding to MKN-45 cells. 
This is considerable for the extravasated Fab'-PEG immuno-
liposomes, because Fab'-PEG immunoliposomes can bind 
readily with MKN-45 cells in vitro binding assay shown in 
Fig. 2. This is particularly important for many endocytotic 
internalization of bioactive materials. Its use in receptor-medi-
ated drug targeting should be investigated. 
In summary, we have designed a new type of long-circulat-
ing immunoliposome which can be extravasated to the tar-
geted solid tumor in vivo. The formulation retains specific 
antigen-binding ability to target cells after extravasation. 
Such liposomes should be able to provide a high local con-
centration of an encapsulated drug at the target site. Uptake 
of immunoliposomes by target cells is considered to occur via 
receptor-mediated endocytosis. A future possibility is to con-
jugate other ligands to the free PEG terminals of Fab'-PEG 
immunoliposomes, in order to direct the liposomes to surface 
receptors known to be internalized at a high rate by cells. 
Such liposomal formulations should be useful for endocytotic 
internalization of plasmid DNA. 
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